Health
STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
- Published
- (1 h ago)
- Outlet
- STAT News
- Section
- Health
- Length here
- Headline and 19-word snippet. The full article is at the source.
More from STAT News and around the same time
STAT+: Amid Mass General Brigham layoffs, CEO pens vague letter, stirring staff anxietyA cryptic email sent to Mass General Brigham employees by the health system's CEO is stirring staff anxiety less than two weeks after a round of layoffs.STAT+: Who will get the first psychedelic approved?The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved. But it could be a tight race, with a non-profit…STAT+: What do the midterms mean for health care?STAT unpacks what the midterms mean for health policy, MAHA, and health insurance.STAT+: FDA, CMS look to collaborate with states on health AIIn this edition of STAT Health Tech: Federal officials look to work with states on regulating AI, protecting doctors from AI liability, and more.STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and moreThe FDA gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicineChild dies of measles in New York’s first such death in 30 yearsA child in rural northern New York has died after contracting measles, marking the state's first death from the disease in 30 years.This page holds the headline and a short snippet as published by STAT News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
